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Background: The objective was to evaluate the diagnostic value of RHD fetal genotyping from the plasma of  
D- mothers as soon as 10 weeks' gestation in a routine clinical practice in Belgium.  
Study design and methods: A prospective study was conducted between November 2002 and December 2006. 
DNA extraction was performed in an automated closed tube system. Fetal RHD/SRY genotypes were detected in 
the plasma of 563 pregnant mothers by real-time polymerase chain reaction (PCR) targeting multiple exons 4, 5, 
and 10 of the RHD gene and targeting an SRY gene sequence. These were compared to the D phenotypes 
determined in the 581 babies they delivered. 
Results: By combining amplification of three exons, the concordance rate of fetal RHD genotypes in maternal 
plasma and newborn D phenotypes at delivery was 100 percent (99.8% including one unusual false-positive). 
The presence of nonfunctional RHD genes and the absence of a universal fetal marker, irrespective of fetal sex, 
did not influence the accuracy of fetal RhD status prediction. The RHD genotyping from 18 twin pregnancies 
was also assessed. Five weak D women were excluded from the RHD fetal genotyping prediction. Three 
discrepant results (0.5%) between predicted fetal genotype and cord blood phenotype were not confirmed by the 
baby phenotypes from venipuncture blood. 
Conclusion: Prenatal prediction of fetal RHD by targeting multiple exons from the maternal plasma with real-
time PCR is highly sensitive and accurate. Over 4 years, this experience has highly modified our management of 
D- pregnant women. 
Abbreviations: Ct = cycle threshold; HDFN = hemolytic disease in fetuses and newborns. 
 
Despite the use of anti-D immunoglobulin (RhIG) prophylaxis, RhD (D) alloimmunization still remains the 
major cause of severe hemolytic disease in fetuses and newborns (HDFN).1 ABO/D, Rh/Kell typing of red cells, 
and alloantibody detection in the blood of pregnant women is routinely performed to identify pregnancies at risk 
for HDFN, to identify D- women who need RhIG prophylaxis, and to provide compatible blood for obstetric 
emergencies.2 When anti-D is detected, the knowledge of fetal D status aids in the management of HDFN. When 
using this approach, it was custom to phenotype the putative father (Fig. 1). Based on the probability that the 
fetus had inherited the RHD gene (RHD), serial assessment of maternal antibody titers was performed with 
indirect antiglobulin test (IAT) in saline at 37°C.3 If the titer was high or was rising to a significant level, then 
invasive amniocentesis was made. Measurements of the optical density (∆ΟD450 nm) and fetal RHD genotyping 
were determined from the amniotic fluid. 
In 1998, Lo and coworkers4 demonstrated cell-free fetal DNA in plasma and serum from pregnant women. This 
has led to the development of noninvasive real-time polymerase chain reaction (PCR) assays to detect fetal RHD 
during pregnancy5,6 Antenatal management of anti-D-alloimmunized women has been modified as a result of this 
new molecular approach in combination with Doppler ultrasonography of the fetal middle cerebral artery.7,8 The 
peak systolic waves of middle cerebral artery will gradually supplant amniocentesis to detect severe fetal anemia. 
The time has come to "put the needles away" when assessing D fetal status, evaluating affected fetuses and 
managing pregnancy9 Our clinical diagnostic laboratory implemented this noninvasive fetal RHD genotyping in 
2002. 
Several studies have described fetal RHD genotyping techniques with maternal plasma.10 A few European teams 
in the United Kingdom,11 France,12,13 and the Netherlands14 have reported their experiences with these techniques 
in clinical routine practice.15 This report discusses our experiences in evaluating RHD fetal genotype from the 
maternal plasma of D- mothers in a clinical routine practice in Belgium. 
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MATERIALS AND METHODS 
Subjects 
After informed consent, blood samples from 563 D- pregnant women came from our own gynecology obstetric 
department as well as other Belgian hospitals via post or couriers. The major indications were the management 
of anti-D-alloimmunized patients or patients at risk of D alloimmunization before the use of invasive procedures 
or potentially sensitizing obstetrical events. Since 2006, this noninvasive method for determining fetal RHD 
genotypes has been proposed for all D- pregnant women at our hospital. 
Eighteen patients had a twin pregnancy. The 563 results of the fetal RHD genotype were compared to the 581 D 
phenotypes of the newborns. The mean gestational age at which genotyping was carried out was 19.7 weeks 
(median, 17.5 weeks; range, 10-38 weeks). Forty women were tested during the first trimester (<14 SA; 7.1%), 
409 were tested during the second trimester (<27 SA; 72.7%), and 114 were tested during the third trimester 
(20.2%). Twenty-two pregnant women were of black African origin. 
Samples 
Maternal (and paternal) peripheral blood was collected in evacuated tubes containing ethylenediaminetetraac-
etate and stored at room temperature. Most samples were received within 24 hours of blood collection, and after 
48 hours, the samples were no longer used. Within 48 hours, the blood samples were centrifuged at 1700 × g for 
10 minutes. The maternal plasma was transferred to three polypropylene sterile microtubes and frozen at less 
than -20°C until further processing. The maternal (and paternal) buffy coat was separately frozen under the same 
conditions. Cord blood samples were provided at birth to confirm the D status of fetuses by Rh serotyping. In 
mothers undergoing amniocentesis, RHD genotyping was also confirmed from the amniotic fluid. 
DNA extraction 
Automatic DNA extraction was performed with an automated sample preparation system (Cobas Ampliprep, 
Roche Diagnostics, Vilvoorde, Belgium) with the total nucleic acid isolation kit (Roche Diagnostics). DNA was 
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extracted from 850 µL of maternal plasma, the maximal volume to be processed by the instrument. The final 
elution volume was 70 µL. A 10-µL aliquot of the extracted DNA was used for amplification. Two extractions 
per women were made from two aliquoted micro-tubes. When relevant, 200 µL of buffy coat and 500 µL of 
amniotic fluid samples were extracted in the same manner. Eluate from the buffy coat was prediluted at 1 in 
1000. Two internal controls were added to each extraction series: a positive control extracted from the buffy coat 
of a D+ man, at a concentration of 20 to 80 ng per µL, diluted (1/1000 vol/vol) with plasma from a D-women, 
and a negative control consisting of plasma from a D- women. 
RHD genotyping 
Quantitative real-time PCR was performed with the TaqMan technology with a sequence detector (ABI Prism 
7700, Applied Biosystems, Foster City, CA) and primers and probes synthesized by Eurogentec (Liège, 
Belgium). To enhance specificity, three regions in the RHD (exons 4, 5, and 10) were targeted. The 
characteristics and sequences of the primers and probes used in the RHD real-time PCR assays were similar to 
those previously reported.16 In brief, RHD exons 4 and 5 were adapted from Finning and colleagues,17 generating 
a 71- and 82-bp amplicon, respectively. These real-time PCR assays detected RHD but not the nonfunctional 
RHDψ or RHD-CE-D hybrid genes. Real-time PCR of the 3'UTR from RHD exon 10 was identical to that shown 
by Lo and coworkers5 (74-bp amplicon). With this last assay, the exon 10 sequence of RHDψ or RHD-CE-D 
hybrid genes was also amplified. To evaluate the efficiency of the DNA extraction procedure and to confirm that 
male fetal DNA was present in the maternal plasma, CCR5 (the universal chemokine receptor gene) and the Y-
chromosome linked SRY gene sequence (83-bp amplicon) were amplified. 
To improve sensitivity, two real-time PCR replicates per RHD exon were carried out. The final elution volume 
from one extraction (70 µL) did not allow to analyze each PCR in duplicate (10 µL per PCR). Therefore, one 
real-time PCR per RHD exon was done, respectively, on each extract. A duplex real-time PCR amplified exon 
10 and CCR5 in the same well. Each extract was tested for SRY in a monoplex and an SRY/exon 5 duplex real-
time PCR. 
Amplification results were reported by cycle threshold (Ct), that is, the calculated cycle number at which the 
PCR products crossed a detection threshold. The higher the initial amount of target DNA, the lower the Ct value. 
Interpretation criteria 
A fetus was characterized as RHD+ if at least one of two replicates was positive for all three RHD exons. When 
there were discrepancies between the three RHD exons, real-time PCR assays targeting the exons with negative 
results were repeated on two additional replicates prepared from a new extract of the last preserved maternal 
plasma. The maternal (and paternal) buffy coats were tested with the same assay. If the discrepancy persisted 
without any amplification of maternal genomic DNA, the result was considered inconclusive and a new blood 
sample was obtained for reanalysis. Males were predicted if at least two of four SRY results were positive. 
To prevent false-positive due to RHDψ or RHD-CE-D  hybrid genes, fetuses were considered negative when no 
amplifications were detected for both RHD exon 4 and RHD exon 5 whatever the PCRs of exon 10. In the case 
of isolated amplification of exon 10, a conventional PCR-based test for detecting RHD, RHDψ, the C and c 
alleles of RHCE (described by Singleton et al.18), was performed from the maternal (and paternal) genomic DNA 
of conserved white blood cells (WBCs) to confirm the presence of a nonfunctional gene. The partner was 
analyzed when the exon 10 real-time PCR on maternal buffy coat was negative. 
When the Ct from three RHD exons was abnormally low (<5th percentile), real-time PCR was performed on 
maternal WBC DNA to assess the presence of maternal RHD. The real-time-PCR was considered negative when 
no signal was observed before the 45th cycle of amplification. 
 
RESULTS 
Correlation between the results of RHD genotyping of DNA from the maternal plasma and the RhD 
phenotypes of newborns 
For the 545 singleton pregnancies, fetal RHD and SRY genotyping from the maternal plasma predicted 90 RHD-/ 
SRY- fetuses, 95 RHD-/SRY+ fetuses, 176 RHD+/SRY-fetuses, and 184 RHD+/SRY+ fetuses. A total of 544 
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results were confirmed by the birth of 266 girls, of whom 90 were D- and 176 D+, and the birth of 278 boys, of 
whom 95 were D- and 183 D+. Overall, 66.1 percent of RHD+ fetuses and 33.9 percent negative were found, 
51.2 percent of SRY+ fetuses and 48.8 percent negative were observed (Table 1). Sensitivity of the D status 
prediction was thus 100 percent (no false-negatives). The specificity was 100 percent after the exclusion of one 
unusual false-positive from the plasma of a solid organ transplant recipient. This last one was observed in a  
37-year-old D- pregnant patient who had received an amniocentesis to determine the fetal karyotype, as 
previously reported.19 The patient was 16.6 weeks pregnant, and real-time PCR in the maternal plasma showed 
amplification of exons 4, 5, 10, and SRY, indicating that the fetus was a D+ male. Ct values of the amplifications 
were identical to those observed for the other D+ male fetuses (mean Ct of exons 4, 5, 10, and SRY were 40.4, 
37.1, 38.7, and 38.8, respectively). The real-time PCR of all exons and SRY were negative in the amniotic cells. 
This discrepancy between invasive and noninvasive results invalidated fetal RHD genotyping from the maternal 
plasma. The patient's history told us that the patient had received a kidney transplant from a D+ male donor. In 
October 2005, a D- girl was born. It should be noted that the RHD and SRY were still found in the maternal 
plasma 3 days after birth. 
Three other results revealed discrepancies between the fetal genotype and cord blood phenotype. These three 
discrepancies (0.5%) are worth commenting on (Table 2). In the first case, baby venipuncture, for diagnostic 
purpose, confirmed that the phenotype and genotype matched. In the second case, the mother refused a 
venipuncture for her baby but accepted a buccal swab. The RHD genotype deduced from the buccal cells was 
similar to that determined from maternal plasma. None of these mothers received the appropriate RhIG 
prophylaxis. In the third case, the obstetrician reported a discrepancy between the genotype and newborn 
phenotype. It was recommended that an ABO/D control group and a search for a weak D be included. These 
analyses confirmed the RHD genotype result. Moreover, the direct antiglobulin test result was negative. 
No discrepancies were found with regard to sex prediction in the whole series. 
 
TABLE 1. Singleton pregnancies: correlation between RHD genotyping of DNA from maternal plasma and the 
RhD phenotypes of the newborns at birth 
Fetal RHD genotyping from maternal plasma Gestation 
(weeks) 
 
Number RHD+/RHD- SRY+/SRY- 
Concordant 
results* (%) 
10-13 39 26/13 21/18 100 
14-26 396 260/136 195/201 100† 
27-38 110 74/36 63/47 100 
Total 545 360/185 (66.1%/33.9%) 279/266 (51.2%/48.8%) 100† 
* Concordant results confirmed by fetal D phenotyping on baby blood samples and infant sex.  
† 100 percent concordance when the patient with a kidney transplant from a D+ male kidney donor was excluded. 
 
Ct value of each real-time PCR assay: descriptive statistics 
The amplification efficiencies of the assays specific for RHD exons 5, 10, and SRY were comparable, each 
having a similar median Ct value. A lower efficiency was observed for exon 4, however (Table 3). The Ct values 
of different real-time PCR assays, with the exception of the CCR5 assay, correlated poorly with gestation age. 
Correlation coefficients were between 0.2 and 0.4. All slopes were negative and significantly different from zero 
(data not shown). 
The sensitivity of each real-time PCR assay (the number of positive replicates out of the total performed from 
the D+ fetuses) was 86.8, 97.1, and 96.9 percent for exons 4, 5, and 10, respectively. Sensitivity for SRY (the 
number of positive replicates out of the total performed from the male fetuses) was 94.9 percent. Seventy-seven 
of 360 women bearing a D+ fetus exhibited at least one negative replicate and 19.5 percent (15/77) presented 
two negative replicates for a specific RHD exon. Fourteen of them showed two negative replicates for exon 4 
(3.9%), none for exon 5, and one for exon 10 (0.3%). In these 15 patients with failed amplification of exons 4 or 
10, real-time PCR was repeated in duplicate from a third extraction of preserved maternal plasma and the 
absence of exon 4 amplification remained only for two. Real-time PCR on the maternal buffy coat DNA did not 
reveal amplification of the RHD gene region. The fetal RhD status predictions were inconclusive for these two 
patients and required a new blood sample from patients to provide conclusive results. 
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The absence of amplification was not related to gestational age. Indeed, of 77 patients, the mean gestational age 
was 19.7 weeks (median, 17.5 weeks), compared to 18.6 weeks (median, 17.1 weeks) in the 283 others. The 
difference was not significant (p = 0.14; t = 1.489). No extraction failures of fetal DNA was observed, that is, all 
negative PCR results from the first extract with all positive PCR results from the second one. 
 
















gw RHD SRY RhD sexe RhD sexe RHD SRY 
1. SM 16 + + - + + + NA NA 
2. BF 22 + - - - NA NA +† -† 
3. NM 25.3 + - -‡ - +§ - NA NA 
4.  FI 16.6 + + - - - - -II -II 
*   Identical serologic methods. 
† Buccal cells. 
‡ Weak D testing not performed. 
§ Weak expression of D. 
II Amniocytes. 
gw = gestation weeks; + = presence; - = absence; NA = not available. 
 
TABLE 3. Ct value of each real-time PCR assay: descriptive statistics 
Target Mean Minimum 5th percentile Median 95th percentile Maximum
RHD exon 4 40.2 34.9 37.8 40.1 42.6 44.0 
RHD exon 5 36.4 31.5 34.0 36.4 38.7 43.7 
RHD exon 10 36.9 29.4 34.5 36.9 39.3 42.7 
SRY monoplex 37.4 32.3 35.2 37.3 39.8 43.0 
SRY duplex* 37.2 30.9 35.0 37.1 39.6 42.0 
CCR5†  35.5 25.8 33.1 35.5 37.8 43.0 
* SRY duplex = assay for exon 5 and SRY.  
†  Duplex assay for exon 10 and CCR5. 
TABLE 4. Examination of patients with isolated exon 10 amplification 
  
Real-time PCR on 
maternal plasma 
exons 4, 5, and 10 
Real-time PCR on 
buffy coat maternal 
exons 4, 5, and 10    
Patients 
Racial 










1 A/A + (30.7) - + - cde/cde Maternal RHDψ cde/cde 
2 A/A + (32.7) - + - cde/cde Maternal RHDψ cde/cde 
3 A/A + (32.4) - + - cde/cde Maternal RHDψ cde/cde 
4 A/U + (33.7) - + - cde/cde Maternal RHDψ cde/cde 
5 C/A + (35.7) - - - cde/cde Paternal RHDψ cde/cde 
6 C/A + (34.9) - - - cde/cde Paternal RHDψ cde/cde 
7 C/A + (37.0) - - - cde/cde Paternal RHDψ cde/cde 
8 A/U + (33.1) - + - Cde/cde Maternal RHD-CE-D cde/cde 
9 A/A + (30.1) - + - Cde/cde Maternal RHD-CE-D Cde/cde 
10 A/A + (35.5) - - - cde/cde Paternal RHD-CE-D Cde/cde 
A = Black African; C = Caucasian; U = Unknown; 5th percentile of exon 10 Ct value, 34.5. 
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TABLE 5. Weak D women excluded from prenatal prediction 
Ct value (mean)   
  
SRY 
Patients gw Exon 4 (P5, 
37.8) 
Exon 5 (P5, 
34.0) 
Exon 10 (P5, 34.5) du. (P5, 
35.0) 




1 14.5 36.0 31.8 32.7   ccEe 
2 17.0 37.2 33.0 33.9 37.0 37.8 ccEe 
3 16.0 35.4 30.8 31.8 36.7 38.3 ccEe 
4 17.2 36.1 32.3 33.6 36.5 37.1 Ccee 
5 20.3 36.8 32.4 32.6 37.4 38.1 ccee 
gw = gestational week; du. = duplex assay for exon 5 and SRY; mo. = monoplex assay; P5 = 5th percentile. 
 
Examination of patients presenting isolated amplification of exon 10 
For exon 4 and 5 real-time PCR, the specificity was 100 percent (no sequences were amplified for any 
pregnancies with D- fetuses) except for one unusual false-positive. The fetal RhD status prediction was accurate 
in spite of maternal or paternal nonfunctional genes. Ten patients with isolated amplification of exon 10 gave 
birth to 10 D- newborns (Table 4). The specificity of exon 10 real-time PCR was 94.6 percent. The patients were 
either black African or had a black African partner. RHD geno-typing on maternal-paternal WBC DNA 
confirmed the presence of RHDψ in four women and three partners, and the presence of a hybrid RHD-CE-D 
gene was suggested in two women and one partner. The hybrid gene was associated with the Cde haplotype. In 
our small population of black African women bearing a RHD- fetus (n = 9), the frequency of those carrying an 
RHDψ gene was 44 percent (4/9) and the frequency of those harboring a hybrid gene was 22 percent (2/9). When 
the Ct value of exon 10 amplification was less than 34.5 (5th percentile), this suggested that the silent gene was 
of maternal origin. A Ct value of greater than 34.5 suggested that the fetus had inherited a silent gene from his 
father. 
Weak D women were excluded from prenatal prediction 
Fetal RHD genotypes could not be determined from five specimens (0.9%) of patients typed as D- (Table 5). In 
these patients, all real-time PCR assays of the RHD sequences had a Ct value of less than the 5th percentile, a 
value too low to be automatically attributable to fetal origin. The Ct value of SRY real-time PCR was high when 
the fetal sex was male. Analysis of DNA from the maternal WBCs, however, revealed RHD sequences in the 
maternal genome. The search for weak expression of the D antigen with IAT confirmed these results. It should 
be noted that four of five patients presented either Cde or cdE haplotypes. 
Three RHD- D- patients (0.5%), bearing a RHD+ fetus, also had Ct real-time PCR assay results in the lower 5th 
percentile. The fetuses were predicted D+ because their mothers had neither a weak expression of D by IAT nor 
RHD exon 4, 5, and 10 sequences in their genome. 
Results of twin pregnancies 
Fetal RHD genotyping from the plasma was performed on 18 twin pregnancies (Table 6). The incidence of twin 
pregnancies was 3.2 percent. The absence of RHD sequence amplification excluded the presence of RHD in the 
twins (no false-negative results were observed). RHD+ real-time PCR predicted at least one D+ fetus. 
 
DISCUSSION 
The correlation between Ct value and week of gestation is not surprising because the concentration of cell-free 
fetal DNA increases with gestational age.20 The wide range of Ct values in each real-time-PCR and the poor 
repeatability of some replicates was partly due to the variability of target copy number in the maternal plasma. 
The variability of Ct value between RHD exon (and SRY) amplification was probably attributable to individual 
sampling variation in the extracted DNA eluates or differences in the efficiency and sensitivity of each real-time 
PCR assay. These data highlight the importance of performing several replicates from each maternal sample and 
Published in : Transfusion (2008), vol. 48, iss. 2, pp. 373-381 
Status: Postprint (Author’s version) 
of testing several RHD-specific sequences to increase the probability of fetal DNA detection and avoid false-
negatives. A total of 3.9 percent of D+ fetus would have been missed if testing for exon 5 and/or exon 10 had 
been omitted. Chan and colleagues21 suggest that most fetal-derived DNA molecules in the maternal circulation 
are small (<313 bp in length).21 This does not explain, however, the lower real-time PCR sensitivity for exon 4, 
because the length of the exon 4 amplicon is similar to those of other RHD amplicons. Another hypothesis would 
state that real-time PCR for exon 4 would be less sensitive because the cell-free fetal DNA is not randomly 
fragmented and the digestion site is located within the chosen sequence of DNA for amplification.22
The SRY-based internal positive control is only applicable for pregnancies carrying a male fetus. Indeed, the 
extent to which negative amplification of both the RHD-and the SRY-specific sequences is predictive of an RHD-
female fetus or a false-negative result due to low fetal DNA concentration cannot be determined. This is why a 
universal positive control to detect fetal DNA has recendy been proposed.23 This is based on the detection of a 
hyper-methylated DNA sequence of RASSF41A. This gene is hypermethylated in placental cells, a major source 
of fetal DNA in the maternal plasma, and hypomethylated in maternal blood cells. Although this approach is less 
complex than the use of other fetal epigenetic markers (hypomethylated maspin)24 or genetic polymorphisms,25 
its feasibility should be evaluated in a routine practice. Nevertheless, neither our lab nor others have observed 
any false-negative results.13,26 Because there are no suitable positive controls for RHD- female fetuses, the 
"Collège National des Gynécologues et Obstétriciens Français" recommends analyzing additional maternal 
plasma samples a few weeks later.27
D- phenotypes and anti-D-alloimmunized people are quite prevalent in Caucasians (15-17%), moderately 
prevalent in Africans (3-5%), and rare in Asian populations (<0.1%).28 In Caucasians, deletion of the entire RHD 
gene is the most common cause of the D-phenotype.29 In contrast, a D- phenotype in Africans and Asians is most 
often the result of an inactive or silent RHD. Sixty-seven percent of D- black Africans have the RHD 
pseudogene, RHDψ, and 15 percent carry a hybrid RHD-CE-Ds gene in which the RHCE segments encompass 
exons 4 through 7.18,30 In this study, the frequency of such genes was 44 and 22 percent, respectively. These two 
nonfunctional alleles contain an intact RHD exon 10 that is recognized by PCR.12,17 The RHD-CE-Ds is 
associated with Cdes haplotype (r's).31 In white persons, antigen D- RHD+ alleles are rare and known to 
preferentially occur in the Cde and cdE haplotypes.32 The molecular bases of these alleles are most frequently 
associated to hybrid RHD-CE-D genes33 with an intact RHD exon 10. Thus, RHD genotyping based solely on the 
RHD-specific sequence in exon10 should not be utilized, and testing of two or more "diagnostic sites" should be 
required to limit the rate of false-positives.34 Moreover, the use of PCR to target multiple exons of the RHD gene 
decreases the probability of not detecting a paternal functional gene with rearrangement inherited by the fetus.35
 
TABLE 6. Results of twin pregnancies: comparison between fetal genotype and twin phenotypes 
Fetal phenotype  Real-time PCR 
genotype First newborn Second newborn 
Patients gw RHD SRY RhD Sex RhD Sex 
 
1 36.2 + + - F + M NA 
2 24.2 - + - M - M mon bia 
3 15.1 + + + M + M bic bia 
4 20.5 + + + F - M NA 
5 18.0 - + - F - M NA 
6 12.0 + - + F + F mon bia 
7 30.0 + + + M + M NA 
8 25.4 + - + F + F mon bia 
9 17.1 + - + F + F NA 
10 14.0 + + + M + M NA 
11 16.0 + + + M + M NA 
12 17.0 + + + M + M bic bia 
13 14.2 + + + M + F bic bia 
14 29.0 - - - F - F NA 
15 29.4 + - + F + F NA 
16 23.0 + + + M + M bic bia 
17 16.2 + + + M + F bic bia 
18 19.5 - + - F - M bic bia 
gw = gestational week; + = positive; - = negative; mon = monochorionic; bic = bichorionic; bia = biamniotic; NA = not available; F = 
female; M = male. 
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The Guidelines for Prenatal and Perinatal Immunohematology (edited by AABB) say that testing apparent  
D-women for weak D expression is not required.36 The majority of individuals with a weak D phenotype are 
weak D types 1, 2, and 3 and cannot so far be anti-D-immunized.37,38 These weak D patients carry a RHD gene 
that encodes for lowered D immunoreactivity. Thus, molecular fetal RHD typing with maternal plasma should 
uncover a maternal RHD gene in these D- women and the risk of erroneously defining the RHD gene as being of 
fetal origin should be considered. For these reasons, we now systematically test for weak D by IAT all  
D- women who are referred for fetal RHD genotyping. Fetal RHD genotyping is not performed in 
nonalloimmunized women with a positive weak D test. 
Some partial D, however, also present a weak expression of D. They constitute a small fraction of weak D 
phenotype. Among these D partial, the DVI are the most frequent in white persons and the carriers are prone to 
anti-D immunization. Therefore, in some countries, testing for weak D is accompanied by tests for DVI or other 
D variants with a selected panel of D-specific monoclonal antibodies directed against different epitopes of D. 
The molecular basis of partial DVI are RHD-CE-D alleles, coding for altered D proteins.39 By real-time PCR 
targeting exons 4, 5, and 10, partial DVI give also an isolated positivity of exon 10.17 This pattern is similar to 
that of RHDψ or RHD-CE-Ds. Therefore, if DVI women are assigned D-(IAT not performed), the knowledge of 
the ethnic origin of both parents is essential because DVI are associated with Caucasians and the two inactive 
genes with Africans. This ethnic information must always be joined with the fetal genotyping request for a 
correct interpretation of results patterns suggesting RHD variants. 
Approximately 0.2 to 1 percent of D- Europeans have a weak D.40 In our study, the prevalence was 5 of 563 
(0.9%). The proportion is higher when the D- patient carries a C or E antigen,33 so an alternative to IAT to detect 
weak D would be to perform a RHD genotyping of serologically D-, C+, and/or E+ pregnant women, before fetal 
DNA typing from her plasma. The fetal RhD status from maternal plasma would be determined with real-time 
PCR targeting the lacking RHD exons in maternal genomic DNA. In our series, no positive amplification of 
RHD exons 4, 5, and 10 of maternal origin was found in women typed D- by IAT. 
In the first two discordant cases (Cases 1 and 2), an error in cord blood collection was the most probable 
explanation (Table 2). Because of the frequency of this type of error (e.g., poor identification or mixture of cord 
blood with maternal blood) and to decrease the incidence of anti-D alloimmunization, the French Society of 
Blood Transfusion (SFTS) and the French Society of Perinatology (SFMP) recommend ABO/RhD typing a cord 
sample of all babies born from a D- mother and in the case of D-results, controlling for the D of the newborn by 
a second blood sample.41 Infants born from D- women should be tested not only for D but also for weak D so 
that appropriate RhIG prophylaxis can be administered to the mother36 (Case 3). Most false-positive RHD typing 
results are due to silent RHD variants or the RHD of weak D patients. The presence of donor-specific DNA in 
the plasma of organ recipients, however, as was observed in Case 4, may also lead to a false-positive result. 
Previous studies indicate that in organ transplantation recipients, microchimerism is present in peripheral blood 
and plasma.42 Thus, we strongly recommend conducting a thorough clinical history, including questions about 
solid organ and stem cell transplantation, before performing analyses. 
Twin pregnancies run a higher risk of obstetrical complications, explaining their high prevalence in our maternal 
intensive care center. Fetal RHD genotyping also helps clinicians to manage twin pregnancies from D- mothers. 
The accuracy of prediction depends on whether the twins' status is dizygotic or monozygotic. No significant 
association was found between the concentration of fetal DNA (Ct value) in the maternal circulation and 
chorionicity during pregnancy.43
Since 2006, noninvasive fetal RHD genotyping has been proposed to all D- pregnant women at our hospital. 
Although no national policy about the systematic antenatal RhIG prophylaxis exists in Belgium, this is proposed 
locally, at 28 weeks' gestation, to our patients bearing D+ fetuses. In several European countries where routine 
antenatal RhIG prophylaxis is offered to all D- pregnant women, large-scale studies are being conducted to 
enable such a strategy.44-46 The feasibility of mass testing for the fetal RHD genotype with maternal plasma is 
highly desirable for ethical and economical reasons. Indeed, it avoids unnecessary administration of RhIG, 
blood-derived products, to approximately 40 percent of D- women bearing D- fetuses. Moreover, these teams are 
evaluating automated approaches not only to allow a mass screening but also to decrease the assay costs below 
the price of RhIG, with a high accuracy of fetal RHD prediction. In the Dutch situation, the implementation of 
this strategy is cost-effective.45 
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CONCLUSIONS 
Noninvasive fetal RHD genotyping by targeting multiple exons with real-time PCR is highly sensitive and 
accurate. It is the best method for assessing D fetal status in D-mothers and is the first step in identifying fetuses 
at risk for anti-D HDFN at the time of the first affected pregnancy or any subsequent ones. Our algorithms for 
the clinical management of Rh D- anti-D-alloimmunized patients that were initially derived from Moise35 have 
been consistently modified for four years. They simplify the routine serologic testing of D- non-anti-D-
immunized women bearing an RHD- fetus and promote the use of antenatal RhIG prophylaxis in a rational 
approach. From a more human and psychological viewpoint, this method decreases patients' anxiety on the basis 
of concrete arguments. It is important for any laboratory that plans to practice this type of analysis to have good 
expertise in the fields of immunohematology and molecular biology. A close relationship with obstetricians and 
pediatricians is also essential. 
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